For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and the formulated version represents a significant advancement . These groundbreaking therapies preserve the transthyretin protein, slowing its harmful build-up and reducing the severity of the condition . Patients are now … Read More